Pulmonary hypertension in patients with a history of intravenous drug use

References

• Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50.
   PubMed Web of Science ®Google Scholar
• Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PloS One. 2014;9(5):e97596.
   PubMed Web of Science ®Google Scholar
• Barnett CF, Hsue PY. Human immunodeficiency virus-associated pulmonary arterial hypertension. Clin Chest Med. 2013;34(2):283–292.
   PubMed Web of Science ®Google Scholar
• Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003;167(10):1433–1439.
   PubMed Web of Science ®Google Scholar
• Sangal RB, Taylor LE, Gillani F, et al. Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection. Ann Am Thorac Soc. 2014;11(10):1553–1559.
   PubMedGoogle Scholar
• Manga P, McCutcheon K, Tsabedze N, et al. HIV and nonischemic heart disease. J Am Coll Cardiol. 2017;69(1):83–91.
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41.
   PubMed Web of Science ®Google Scholar
• Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS (London, England) 2008;22(Suppl 3):S35–S40.
   PubMedGoogle Scholar
• Rasmussen LD, Dybdal M, Gerstoft J, et al. HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study. HIV Med. 2011;12(4):202–210.
   Web of Science ®Google Scholar
• Auerbach E, Aboulafia DM. Venous and arterial thromboembolic complications associated with HIV infection and highly active antiretroviral therapy. Semin Thromb Hemost. 2012;38(8):830–838.
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Rieckmann P, Sinowatz F, et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol (Baltimore, Md: 1950). 1993;150(10):4601–4609.
   PubMed Web of Science ®Google Scholar
• Caldwell RL, Gadipatti R, Lane KB, Shepherd VL. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells. J Leukoc Biol. 2006;79(1):192–201.
   PubMed Web of Science ®Google Scholar
• Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351(16):1655–1665.
   PubMed Web of Science ®Google Scholar
• Almodovar S, Knight R, Allshouse AA, et al. Human immunodeficiency virus nef signature sequences are associated with pulmonary hypertension. AIDS Res Hum Retrovir. 2012;28(6):607–618.
   PubMed Web of Science ®Google Scholar
• Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS (London, England). 2010;24(1):67–75.
   PubMed Web of Science ®Google Scholar
• Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis. 2004;38(8):1178–1185.
   PubMed Web of Science ®Google Scholar
• Pal J, Sen K, Sarkar G, et al. Effect of antiretroviral therapy on pulmonary hypertension in HIV patients. J Indian Med Assoc. 2013;111(12):845–6, 9.
   PubMedGoogle Scholar
• Cicalini S, Chinello P, Grilli E, Petrosillo N. Treatment and outcome of pulmonary arterial hypertension in HIV-infected patients: a review of the literature. Curr HIV Res. 2009;7(6):589–596.
   PubMed Web of Science ®Google Scholar
• Chinello P, Cicalini S, Pichini S, et al. Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor. Infect Dis Rep. 2015;7(1):5822.
   PubMed Web of Science ®Google Scholar
• Venitz J, Zack J, Gillies H, et al. Clinical pharmacokinetics and drug–drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012;52(12):1784–1805.
   PubMed Web of Science ®Google Scholar
• Condliffe R, Elliot CA, Hurdman J, et al. Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre. Ther Adv Respir Dis. 2014;8(3):71–77.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Tsujino I, Sato T, et al. Hemodynamic effects of ambrisentan–tadalafil combination therapy on progressive portopulmonary hypertension. World J Hepatol. 2014;6(11):825–829.
   PubMedGoogle Scholar
• Eriksson C, Gustavsson A, Kronvall T, Tysk C. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointest Liver Dis. 2011;20(1):77–80.
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2012;141(4):906–915.
   PubMed Web of Science ®Google Scholar
• Faisal M, Siddiqi F, Alkaddour A, et al. Effect of PAH specific therapy on pulmonary hemodynamics and six-minute walk distance in portopulmonary hypertension: a systematic review and meta-analysis. Pulm Med. 2014;2014:528783.
   Google Scholar
• Sag S, Yesilbursa D, Gullulu S. Treatment with a combination of bosentan and sildenafil allows for successful liver transplantation in a patient with portopulmonary hypertension. Turkish J Gastroenterol. 2014;25(4):429–432.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25(3):502–508.
   PubMed Web of Science ®Google Scholar
• Nayak RP, Li D, Matuschak GM. Portopulmonary hypertension. Curr Gastroenterol Rep 2009;11(1):56–63.
   PubMedGoogle Scholar
• Seyfarth HJ, Favreau N, Tennert C, et al. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension. Ann Hepatol. 2014;13(6):803–809.
   PubMed Web of Science ®Google Scholar
• Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest. 2011;139(1):109–114.
   PubMed Web of Science ®Google Scholar
• Halank M, Knudsen L, Seyfarth HJ, et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol. 2011;49(9):1258–1262.
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006;28(3):563–567.
   PubMed Web of Science ®Google Scholar
• DuBrock HM, Channick RN, Krowka MJ. What’s new in the treatment of portopulmonary hypertension? Expert Rev Gastroenterol Hepatol. 2015;9(7):983–992.
   PubMed Web of Science ®Google Scholar
• Olsson KM, Delcroix M, Ghofrani HA, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 2014;129(1):57–65.
   PubMed Web of Science ®Google Scholar
• Austin MJ, McDougall NI, Wendon JA, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transplant 2008;14(3):287–291.
   PubMed Web of Science ®Google Scholar
• McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clin Toxicol (Philadelphia, Pa). 2018;56(9):1–9.
   Web of Science ®Google Scholar
• Renard S, Borentain P, Salaun E, et al. Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir. Chest. 2016;149(3):e69–73.
   PubMed Web of Science ®Google Scholar
• Caravita S, Secchi MB, Wu SC, et al. Sildenafil therapy for interferon-beta-1a-induced pulmonary arterial hypertension: a case report. Cardiology. 2011;120(4):187–189.
   PubMed Web of Science ®Google Scholar
• Savale L, Sattler C, Gunther S, et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J. 2014;44(6):1627–1634.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Kaker A, Dosanjh A, et al. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Dig Dis Sci. 2010;55(6):1785–1790.
   PubMed Web of Science ®Google Scholar
• Terra Filho M, Yen CC, Santos Ude P, Munoz DR. Pulmonary alterations in cocaine users. Sao Paulo Med J 2004;122(1):26–31.
   PubMedGoogle Scholar
• Yakel DL Jr, Eisenberg MJ. Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J. 1995;130(2):398–399.
   PubMed Web of Science ®Google Scholar
• Murray RJ, Smialek JE, Golle M, Albin RJ. Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization. Chest. 1989;96(5):1050–1053.
   PubMed Web of Science ®Google Scholar
• Darke S, Duflou J, Torok M. The health consequences of injecting tablet preparations: foreign body pulmonary embolization and pulmonary hypertension among deceased injecting drug users. Addiction (Abingdon, England). 2015;110(7):1144–1151.
   PubMed Web of Science ®Google Scholar
• Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest. 2006;130(6):1657–1663.
   PubMed Web of Science ®Google Scholar
• Dempsie Y, Maclean MR. Role of the serotonin transporter in pulmonary arterial hypertension. Expert Rev Clin Pharmacol. 2008;1(6):749–757.
   PubMedGoogle Scholar
• Paratz ED, Cunningham NJ, MacIsaac AI. The cardiac complications of methamphetamines. Heart Lung Circ. 2015;25(4):325–332.
   PubMed Web of Science ®Google Scholar
• Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9):609–616.
   PubMed Web of Science ®Google Scholar
• Ho RC, Ho EC, Tan CH, Mak A. Pulmonary hypertension in first episode infective endocarditis among intravenous buprenorphine users: case report. Am J Drug Alcohol Abuse. 2009;35(3):199–202.
   PubMed Web of Science ®Google Scholar
• Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2011;364(4):351–360.
   PubMed Web of Science ®Google Scholar
• Yuan SM. Right-sided infective endocarditis: recent epidemiologic changes. Int J Clin Exp Med. 2014;7(1):199–218.
   PubMed Web of Science ®Google Scholar
• Hind CR. Pulmonary complications of intravenous drug misuse. 2. Infective and HIV related complications. Thorax. 1990;45(12):957–961.
   PubMed Web of Science ®Google Scholar
• Heiberg J, Ilkjaer LB. Pulmonary endarterectomy after pulmonary infectious embolisms. Interact Cardiovasc Thorac Surg. 2013;16(4):556–557.
   PubMed Web of Science ®Google Scholar